Biotech Values

[DewDiligence]

ENTA—It's my opinion M&A dealings fall outside the parameters of the 8-K release. I would not consider [M&A] part of normal day-to-day operations which the key sentence (above) points to… There's enough legal wiggle room to support this idea.

Agree that there may be wiggle room in the 8-K statement for disagreements on M&A, specifically; however, issuing the 8-K qualification, which wasn’t obligatory, strikes me as playing unduly close to the (legal) edge. So the bottom line continues to be that I’m not sure what’s going on.